Daily3d
Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis
Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Le Lézard6d
Talkdesk again earns a spot on G2's 2025 Best Software Awards for Best Customer Service Products
Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, today announced it has been named to G2's 2025 Best ...
Le Lézard6d
Ingram Micro Elevates the Power of Community
Ingram Micro Inc. (NYSE: INGM), a business-to-business (B2B) platform company for the global technology ecosystem, today announced its two partner communities?Ingram Micro SMB Alliance and Ingram ...
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...
Nasdaq14d
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
The increase was driven by higher demand for HBV and HDV drugs, along with incremental sales of Livdelzi (seladelpar) in primary biliary cholangitis (PBC). Veklury sales plunged 53% to $337 ...
Zacks.com on MSN14d
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025. Adjusted earnings per share (EPS) of $1.90 beat the Zacks Consensus Estimate ...
rarediseaseadvisor27d
Seladelpar Leads to Clinically Meaningful Improvements in PBC
52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...
The Pharma Letter29d
FDA approves Ozempic for patients with diabetes and CKD
In an important regulatory win for Denmark’s Novo Nordisk (NOV: N), the US Food and Drug Administration (FDA) yesterday approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, ...
WebMD1mon
Livdelzi: A New Treatment Option for Primary Biliary Cholangitis
Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.